CorMedix Inc (NASDAQ:CRMD – Get Free Report) Director Myron Kaplan purchased 25,000 shares of the stock in a transaction that occurred on Monday, November 16th. The shares were purchased at an average price of $4.88 per share, for a total transaction of $122,000.00. Following the completion of the purchase, the director directly owned 256,487 shares of the company’s stock, valued at approximately $1,251,656.56. This trade represents a 10.80% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
CorMedix Trading Down 3.6%
CorMedix stock opened at $4.50 on Thursday. The business has a 50 day moving average price of $6.96 and a two-hundred day moving average price of $7.52. The company has a quick ratio of 2.36, a current ratio of 2.43 and a debt-to-equity ratio of 0.31. CorMedix Inc has a 12 month low of $4.49 and a 12 month high of $13.02. The stock has a market cap of $357.93 million, a price-to-earnings ratio of 3.62, a price-to-earnings-growth ratio of 1.07 and a beta of 1.48.
CorMedix (NASDAQ:CRMD – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The firm had revenue of $54.52 million for the quarter, compared to analyst estimates of $51.76 million. CorMedix had a return on equity of 26.70% and a net margin of 15.49%. As a group, equities analysts forecast that CorMedix Inc will post 0.44 EPS for the current year.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the stock. Needham & Company LLC lifted their price target on shares of CorMedix from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, November 10th. Weiss Ratings cut shares of CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, November 10th. UBS Group set a $19.00 price objective on shares of CorMedix in a report on Tuesday, November 10th. Wall Street Zen lowered shares of CorMedix from a “hold” rating to a “sell” rating in a research report on Saturday, November 14th. Finally, Oppenheimer reiterated an “outperform” rating and set a $13.00 target price (down from $15.00) on shares of CorMedix in a research report on Friday, November 13th. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.22.
View Our Latest Report on CRMD
Institutional Investors Weigh In On CorMedix
Several institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its position in shares of CorMedix by 167.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,249,382 shares of the company’s stock worth $9,620,000 after purchasing an additional 782,989 shares in the last quarter. Entropy Technologies LP acquired a new position in CorMedix in the third quarter valued at about $332,000. Marshall Wace LLP boosted its position in CorMedix by 53.4% in the third quarter. Marshall Wace LLP now owns 1,195,422 shares of the company’s stock valued at $9,205,000 after buying an additional 415,887 shares in the last quarter. Empowered Funds LLC boosted its position in CorMedix by 10.3% in the third quarter. Empowered Funds LLC now owns 268,323 shares of the company’s stock valued at $2,066,000 after buying an additional 25,091 shares in the last quarter. Finally, Bleakley Financial Group LLC bought a new stake in CorMedix during the third quarter worth about $275,000. Institutional investors and hedge funds own 34.18% of the company’s stock.
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Further Reading
- Five stocks we like better than CorMedix
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
